Transgene Presents 2018 Half-Year Results and Business Update

Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancers and infectious diseases, announces its financial results for the six-month period ended June 30, 2018, and provides an update on its clinical and preclinical portfolio. Philippe Archinard, Chairman and Chief Executive Officer of Transgene, commented, “2018 is a period of intense activity for Transgene. We obtained USD 48 million in the form of Tasly Biopharmaceuticals shares following the sale of TG1050 and TG6002 rights in Greater China. We presented new results on our oncolytic virus Pexa-Vec at ASCO that benefitted from a positive reception. We have continued to make progress with our clinical and preclinical programs. Looking ahead we expect to announce more comprehensive clinical results from our strategic studies before the end of 2018 and over the course of 2019. Our research efforts are focused on our world-leading viral vector expertise applied to our two core technologies: oncolytic viruses and therapeutic vaccines. With our Invir.IO platform, we are designing new viruses to provide a better modulation of the tumor micro-environment. We are also about to present our ambitious approach in neoantigen-based therapeutic vaccines at a scientific congress in the coming weeks. The progress that we have made in 2018 further confirms Transgene’s strategic position as leading innovator in the fight against cancer.” – Medical Buyer Bureau